Proteasome inhibition therapy: assessing the clinical implications in hematologic diseases.
This session addressed the use of proteasome inhibition therapy in multiple myeloma, specifically bortezomib. It also discussed various complications of multiple myeloma and cautions to be taken, specifically regarding osteolytic lesions and renal failure.